EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

The efficacy of standard‐dose versus reduced‐dose everolimus in patients with advanced neuroendocrine tumors: A multicenter retrospective cohort study

Oudai Sahwan iD, Amr Mohamed iD, Fares Jamal iD, Abdullah Alsulaiman iD, Jennah J Bauernfeind, Katherine Myers, Patrick McGarrah iD, Timothy J Hobday, Jason Starr iD, Thorvardur Halfdanarson iD, Mohamad Bassam Sonbol iD

Journal of Neuroendocrinology · 2026-10 · 38 (10)

DOI: 10.1111/jne.70278 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 05.10.2026. Verfasst von Oudai Sahwan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Everolimus, Neuroendocrine Tumors, Antineoplastic Agents. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Everolimus 10 mg daily is the standard dose for advanced neuroendocrine tumors (NETs), but adverse events frequently necessitate dose reduction. As a result, oncologists often adopt a dose‐escalation strategy starting at 5 mg and increasing the dose as tolerated. In this multicenter study, we evaluated the effect of reduced dose (RD) and standard dose (SD) everolimus on survival, progression, and toxicity in patients with advanced NETs. We conducted a multicenter retrospective cohort study of patients with advanced NETs treated with everolimus at Mayo Clinic and University Hospitals (Cleveland, OH). Patients were grouped by starting dose (5 mg vs. 10 mg). Primary endpoints were overall survival (OS), real‐world progression‐free survival (rwPFS), and adverse events. Multivariable Cox models, inverse probability of treatment weighting (IPTW), and time‐varying dose sensitivity analysis were used to account for confounding and dose crossover. Among 170 patients (48 started on 5 mg; 122 on 10 mg), the 5 mg cohort was older, had worse ECOG PS, and was more heavily pretreated. Median OS was 43.7 months (5 mg) versus 81.5 months (10 mg; log‐rank p = .02). However, after multivariable adjustment ( N = 124 G1–G2 patients; 51 events), the association was no longer statistically significant (adjusted HR, 0.59; 95% CI, 0.31–1.12; p = .11). Median rwPFS was 7.0 versus 12.4 months (log‐rank p = .05); the adjusted rwPFS difference was not statistically significant (HR, 0.95; 95% CI, 0.56–1.61; p = .84). Nearly half (46.7%) of 10 mg starters required dose reduction. Any‐grade toxicity was more common with 10 mg (89% vs. 75%; p = .05). The apparent survival advantage of standard‐dose everolimus was substantially attenuated after adjustment. These findings do not establish dose equivalence and should be interpreted in the context of limited statistical power. Given its more favorable observed tolerability profile, RD everolimus warrants prospective evaluation as a starting strategy for patients at increased risk of treatment‐related toxicity who may not tolerate SD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusNeuroendocrine TumorsAntineoplastic AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedDose-Response Relationship, DrugAgedAdultTreatment OutcomeCohort Studies

Stichwörter der Autor:innen

dose reductioneverolimusneuroendocrine tumorsoverall survivaltreatment toxicity

Substanzen

EverolimusAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA.
  • Division of Medical Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
  • Division of Hematology and Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Oudai Sahwan, Amr Mohamed, Fares Jamal, Abdullah Alsulaiman, Patrick McGarrah, Jason Starr, Thorvardur Halfdanarson, Mohamad Bassam Sonbol

Zitieren

APA

Sahwan, O., Mohamed, A., Jamal, F., Alsulaiman, A., Bauernfeind, J. J., Myers, K., McGarrah, P., Hobday, T. J., Starr, J., Halfdanarson, T., & Sonbol, M. B. (2026). The efficacy of standard‐dose versus reduced‐dose everolimus in patients with advanced neuroendocrine tumors: A multicenter retrospective cohort study. Journal of Neuroendocrinology, 38(10). https://doi.org/10.1111/jne.70278

Vancouver

Sahwan O, Mohamed A, Jamal F, Alsulaiman A, Bauernfeind JJ, Myers K, et al. The efficacy of standard‐dose versus reduced‐dose everolimus in patients with advanced neuroendocrine tumors: A multicenter retrospective cohort study. Journal of Neuroendocrinology. 2026;38(10). doi:10.1111/jne.70278

BibTeX
@article{Sahwan2026,
  author = {Sahwan, Oudai and Mohamed, Amr and Jamal, Fares and Alsulaiman, Abdullah and Bauernfeind, Jennah J and Myers, Katherine and McGarrah, Patrick and Hobday, Timothy J and Starr, Jason and Halfdanarson, Thorvardur and Sonbol, Mohamad Bassam},
  title = {The efficacy of standard‐dose versus reduced‐dose everolimus in patients with advanced neuroendocrine tumors: A multicenter retrospective cohort study},
  journal = {Journal of Neuroendocrinology},
  year = {2026},
  volume = {38},
  number = {10},
  doi = {10.1111/jne.70278}
}
Kostenlos starten →